Chargement en cours...
4CPS-264 Population pharmacokinetic model of etanercept in rheumatic disease: prognostic factors and dose recommendations
BACKGROUND: Etanercept is an approved monoclonal antibody for the treatment of rheumatic disease (RD). Individual clinical response to etanercept can be influenced by their pharmacokinetics (PK) and immunogenicity, so therapeutic drug monitoring (TDM) can guide these biologic treatments. PURPOSE: De...
Enregistré dans:
| Publié dans: | Eur J Hosp Pharm |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Group
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535412/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.354 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|